Tom Crowley, Chairman and CEO
Tom has consistently achieved operational success and creation of shareholder value with 10 years in orthopaedics. He brings over three decades of expertise in optimizing profitability in medical device markets. He has successfully completed transactions exceeding 900m, including a 70% IRR exit. Mr. Crowley currently serves on the Boards of Vertical Spine, LLC, Cascade Medical Enterprises, LLC and Myomo, Inc. He is actively engaged in providing governance and business advice involving financial transactions, business strategy and execution to four medical device companies and two private equity firms. Prior to his current role, Thomas was Chairman of Core Essence Orthopedics, Inc., President of Small Bone Innovations, Inc., Managing Director – Healthcare Investment Banking at Friedman Billings Ramsey, Chief Executive at Aircast, LLC, Senior VP and GM, PSS Ventures and VP, Clinical Business Unit at Hoffman LA Roche. Mr. Crowley holds a BA from Fairfield University, Fairfield, CT, MS, Columbia University School of Business, New York, NY and is a Graduate, U.S. Army Command and General Staff College, Ft. Leavenworth, KS.
Chuck Reynolds, S.V.P. Global Sales
Chuck Reynolds is a team oriented, game-changing leader, strategist, and turnaround specialist with more than 20 years of Senior-Level experience in Healthcare Sales, Marketing, and Education. He built, strengthened, and managed comprehensive direct sales force infrastructures and sales distribution networks for established and start-up growing companies in the spinal, trauma, recon, allograft, biologic and regenerative stem cell therapy markets.
Chuck established groundbreaking VIP corporate visits, sales training and medical education programs, which have resulted in exponential growth for several manufacturers, direct sales representatives, distributors, and sales agents. He created and led world-class regional and national sales organizations to achieve sales quotas on a quarterly and yearly basis.
Chuck comes to us with over 25 years in the Spinal, Allograft, Implant and Stem Cell markets with Senior Sales, Distribution, Marketing and Training experience. After graduating from St. Thomas Aquinas College, with a BS in Marketing, Chuck began his earlier career with Zimmer Orthopedics, at the time, division of Bristol Meyers Squibb, which led to the foundation for his strong Managerial Skills. He utilized these talents in Executive Management positions with companies such as Osteotech, Globus Medical, Lanx, and Pioneer Surgical.
Sean O’Connell, Chief Science Officer
Dr. O’Connell received his PhD in immunology and molecular biology from Rutgers University and the University of Medicine and Dentistry of New Jersey at New Brunswick. Additional post-graduate work includes post-doctoral fellowships at the Department of Toxicology, Rutgers University and the Center for Advanced Biotechnology and Medicine. Dr. O’Connell served as an Assistant Professor in the Department of Surgery, R. W. Johnson Medical School in New Brunswick where he was Head of the Surgical Oncology and Flow Cytometry & Immunology Laboratories. Dr. O’Connell received research grants from the New Jersey Cancer Commission, Sandoz/Novartis Pharmaceuticals and American Home Products involving studies in wound healing, host response to biomaterials, solid tumor-host immune response and graft versus host disease. Dr. O’Connell has authored over 65 peer-reviewed publications and abstracts and currently holds the position of Assistant Professor in the Department of Vascular and General Surgery, Englewood Hospital and Medical Center, Mount Sinai School of Medicine.
Dr. O’Connell has served as a partner of Nascent Enterprises, LLC, a medical device venture advisory firm, since Fall 2003. Nascent provides strategic advisory services to numerous medical device clients and portfolio companies. Dr. O’Connell currently serves as Consultant for Cascade Medical Enterprises, LLC (since July, 2003) and as Chief Science Office for Vertical Spine, LLC (since Oct, 2011). Previously Dr. O’Connell served as Director, Medical Affairs for the Transplantation/Tissue Engineering/Immunology Business Unit of Novartis Pharmaceuticals, with responsibility for pre-clinical and clinical development as well as publications and professional relations.